文献速递淋巴瘤白血病

维奈克拉联合方案治疗慢性淋巴细胞白血病Richter转化的多中心研究

A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia.
PubMed 文献 · Blood Adv · 2024-01-01

这项多中心回顾性研究评估了62例接受维奈克拉联合方案治疗的Richter转化患者,联合BTK抑制剂组28例、R-CHOP组13例、其他强化化疗免疫治疗组21例,三组最佳总缓解率/完全缓解率分别为36%/25%、54%/46%、52%/38%。del(17p)与较低完全缓解率相关,TP53突变在维奈克拉初治亚组中与较低完全缓解率和较短无进展生存相关。

要点

  • 维奈克拉联合方案在Richter转化中三组最佳总缓解率分别为36%、54%、52%。
  • del(17p)与总队列较低完全缓解率相关(OR 0.15)。
  • TP53突变仅在维奈克拉初治亚组与不良结局相关。

核心结论

  • 在这一难治性Richter转化人群中,维奈克拉联合方案取得较高缓解率,部分患者获得持久缓解和生存。

研究设计与样本

  • 多中心回顾性研究,纳入62例在临床试验外接受维奈克拉联合方案治疗的Richter转化患者。
  • 联合BTK抑制剂28例,联合R-CHOP 13例,联合其他强化化疗免疫治疗21例。

主要发现

  • 联合BTK抑制剂组最佳总缓解率36%、完全缓解率25%,中位无进展生存4.9个月、中位总生存14.3个月。
  • 联合R-CHOP组最佳总缓解率54%、完全缓解率46%,中位无进展生存14.9个月、中位总生存未达到。
  • 联合其他强化化疗免疫治疗组最佳总缓解率52%、完全缓解率38%,中位无进展生存3.3个月、中位总生存9个月。
  • 总队列中del(17p)与较低完全缓解率相关(OR 0.15;95%CI 0.04-0.6;p=0.01),维奈克拉初治亚组同样相关(OR 0.13;95%CI 0.02-0.66;p=0.01)。
  • 维奈克拉初治亚组中TP53突变与较低完全缓解率(OR 0.15;95%CI 0.03-0.74;p=0.02)和较短无进展生存(HR 3.1;95%CI 1.21-7.95;p=0.02)相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with chronic lymphocytic leukemia (CLL) who develop Richter transformation (RT) have a poor prognosis when treated with chemoimmunotherapy regimens used for de novo diffuse large B-cell lymphoma. Venetoclax, a BCL2 inhibitor, has single-agent efficacy in patients with RT and is potentially synergistic with chemoimmunotherapy. In this multicenter, retrospective study, we evaluated 62 patients with RT who received venetoclax-based treatment outside of a clinical trial, in combination with a Bruton tyrosine kinase inhibitor (BTKi; n=28), rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) (n=13), or intensive chemoimmunotherapy other than R-CHOP (n=21). The best overall and complete response rates were 36%/25%, 54%/46%, and 52%/38%, respectively. The median progression-free and overall survival estimates for the same treatment groups were 4.9/14.3 months, 14.9 months/not reached, and 3.3/9 months, respectively. CLL with del(17p) was associated with a lower complete response rate in the total cohort (odds ratio [OR] 0.15; 95% confidence interval [CI] 0.04-0.6; p=0.01) and venetoclax-naïve subgroup (OR 0.13; 95%CI 0.02-0.66; p=0.01). TP53 mutated CLL was associated with a lower complete response rate (OR 0.15; 95%CI 0.03-0.74; p=0.02) and shorter progression-free survival (hazard ratio 3.1; 95%CI 1.21-7.95; p=0.02) only in venetoclax-naïve subgroup. No other clinical or baseline characteristics, including prior venetoclax treatment for CLL, showed statistically significant association with outcomes. Grade 3-4 neutropenia and thrombocytopenia events were most frequent with intensive chemoimmunotherapy + venetoclax; grade 3-4 infection rates were similar across treatment groups. In this difficult-to-treat RT patient population, venetoclax-based combination regimens achieved high response rates, with durable remission and survival observed in a subset of patients.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Hampel PJ, Swaminathan M, Rogers KA, et al. A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia. Blood Adv. 2024. PMID: 38537065. doi:10.1182/bloodadvances.2023012080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。